Company Overview - Alvotech develops and manufactures biosimilars to increase access to biologic medicines [3] Allegations and Stock Impact - On November 2, 2025, Alvotech announced that the FDA issued a complete response letter for its AVT05 biosimilar application, citing deficiencies found during a July inspection of its Reykjavik manufacturing facility [4] - Following this announcement, Alvotech's stock fell by 34.4%, closing at $5.03 per share on November 3, 2025 [4] Investigation Details - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Alvotech, stemming from allegations of providing potentially misleading business information to the investing public [1][2]

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Company Summaries - **Alvotech SA (NASDAQ:ALVO)**: Received an FDA Complete Response Letter for its AVT05 biosimilar application, leading to a revised outlook for 2025. The stock has fallen approximately 41% over the past month, with a 52-week low of $4.81. Current RSI is 18.8, and shares closed at $5.03 after a 34.3% drop [7] - **Acadia Healthcare Company Inc (NASDAQ:ACHC)**: Set to release third quarter 2025 results on November 5. The stock has decreased around 19% in the past month, with a 52-week low of $17.12. Current RSI is 27.9, and shares closed at $21.31 after a 0.9% decline [8] - **Akebia Therapeutics Inc (NASDAQ:AKBA)**: Reported inducement grants under Nasdaq Listing Rule 5635(c)(4). The stock has fallen about 33% over the past five days, with a 52-week low of $1.52. Current RSI is 29.4, and shares closed at $2.12 after a 4.1% drop [8]